Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified pediatric-style AIEOP LLA-2000 protocol in young adults with acute lymphoblastic leukemia
2009-016075-30Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, dexamethasone, methotrexate, pegaspargase, cyclophosphamide and 3 more in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Primary endpoints: Feasibility at 8 months and Off-study events contributing to feasibility failure. Started Jul 2010; status: completed.
02
Drugs
doxorubicindexamethasonemethotrexatepegaspargasecyclophosphamide
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2009-016075-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016075-30.